Radius Health (NASDAQ:RDUS) Stock Rating Lowered by ValuEngine

Radius Health (NASDAQ:RDUS) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Saturday, ValuEngine reports.

Other analysts have also issued research reports about the company. HC Wainwright reiterated a “hold” rating on shares of Radius Health in a research note on Friday, December 20th. Leerink Swann cut their price target on Radius Health from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Royal Bank of Canada set a $27.00 price target on Radius Health and gave the company a “hold” rating in a research note on Friday, November 1st. Finally, BidaskClub lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $33.43.

RDUS stock opened at $19.97 on Friday. The business’s fifty day simple moving average is $19.43 and its two-hundred day simple moving average is $23.45. Radius Health has a twelve month low of $17.36 and a twelve month high of $29.97. The firm has a market cap of $914.21 million, a price-to-earnings ratio of -6.13 and a beta of 0.89.

Institutional investors have recently made changes to their positions in the company. Great Lakes Advisors LLC increased its stake in shares of Radius Health by 3.6% during the third quarter. Great Lakes Advisors LLC now owns 329,349 shares of the biopharmaceutical company’s stock valued at $8,481,000 after buying an additional 11,489 shares during the period. Boston Advisors LLC increased its stake in shares of Radius Health by 47.8% during the third quarter. Boston Advisors LLC now owns 61,012 shares of the biopharmaceutical company’s stock valued at $1,571,000 after buying an additional 19,722 shares during the period. Rhumbline Advisers increased its stake in shares of Radius Health by 1.3% during the third quarter. Rhumbline Advisers now owns 67,718 shares of the biopharmaceutical company’s stock valued at $1,744,000 after buying an additional 846 shares during the period. Pictet Asset Management Ltd. grew its stake in Radius Health by 10.4% in the third quarter. Pictet Asset Management Ltd. now owns 318,536 shares of the biopharmaceutical company’s stock valued at $8,202,000 after purchasing an additional 30,000 shares during the last quarter. Finally, Voloridge Investment Management LLC purchased a new position in Radius Health in the third quarter valued at about $598,000.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Read More: What Does a Sell-Side Analyst Rating Mean?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.